BGMS insider filing: CFO acquires 200,000 shares at $1.40 common stock

Bio Green Med Solution, Inc. (BGMS) reported an insider transaction on Form 4.

Rhea-AI Filing Summary

Bio Green Med Solution, Inc. (BGMS) reported an insider transaction on Form 4. Director and Chief Financial Officer Kiu Cu Seng acquired 200,000 shares of common stock at $1.40 per share on 11/12/2025.

Following the transaction, the reporting person beneficially owned 200,000 shares, held in direct ownership. The filing was made by one reporting person.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 1 txn

Insider Kiu Cu Seng

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	200,000	$1.40	$280K

Holdings After Transaction: Common Stock — 200,000 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BGMS disclose in this Form 4?

An insider, who is both a Director and Chief Financial Officer, acquired 200,000 shares of common stock at $1.40 on 11/12/2025.

Who is the reporting person in BGMS’s Form 4?

The reporting person is Kiu Cu Seng, serving as Director and Chief Financial Officer.

How many BGMS shares were acquired and at what price?

The insider acquired 200,000 shares at a price of $1.40 per share.

What is the insider’s share ownership after the transaction?

After the transaction, the insider beneficially owned 200,000 shares.

What is the ownership form for the reported BGMS shares?

The shares are held in direct ownership.

When did the BGMS insider transaction occur?

The transaction date was 11/12/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kiu Cu Seng

(Last) (First) (Middle)

LEVEL 10, TOWER 11, AVENUE 5, NO. 8

JALAN KERINCHI

(Street)

KUALA LUMPUR N8 59200

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bio Green Med Solution, Inc. [ BGMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/12/2025		A		200,000	A	$1.4	200,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kiu Cu Seng	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.